American Kidney Fund Statement on Congressional Letter to Secretary Price

Statement from LaVarne A. Burton, President and Chief Executive Officer of the American Kidney Fund

Charitable assistance provides a critical health safety net for our nation’s citizens living with chronic diseases that are complicated and expensive to treat.”

— LaVarne A. Burton

ROCKVILLE, MARYLAND, UNITED STATES, May 31, 2017 /EINPresswire.com/ — Nearly 200 Congressional Democrats and Republicans sent a letter to Health and Human Services Secretary Tom Price this week in a very strong bipartisan effort to urge that HHS protect the right of Americans to rely on help from charities to afford health insurance coverage.

On behalf of the patients we serve—low-income people who need dialysis to stay alive—we are grateful to Reps. Kevin Cramer and Doris Matsui for their leadership on this issue, and to each of the members of Congress who put patients ahead of politics by signing on to the letter.

Americans with life-threatening chronic conditions are facing a crisis in 2017. Increasingly, these policyholders are receiving letters from health insurance companies telling them that no longer will they be allowed to use charitable assistance to pay their insurance premiums. Patients have lost coverage because they cannot pay the premiums on their own. This is a needless crisis that the federal government must address. We are heartened that 40 percent of the House chamber has turned its attention to finding a solution to this serious issue.

Insurers refusing to accept charitable premium assistance for people living with certain chronic illnesses is discriminatory and limits access to coverage for some of the poorest and sickest patients. By engaging in this discriminatory behavior, insurers are threatening the health and financial stability of their policyholders who are living with life-threatening conditions.

Why is this happening?

In 2014, HHS issued interim guidance on the topic of charitable premium assistance for plans in the Affordable Care Act marketplace exchanges. The interim guidance is highly ambiguous and unclear, and some insurers have interpreted it as being a license to refuse all charitable premium payments for certain high-cost patients. They are refusing charitable payments not just for exchange plans, but also for Medicare supplemental coverage and other insurance products.
Patient advocacy groups have been urging HHS for three years to clarify the guidance so that legitimate, bona fide nonprofits like the American Kidney Fund can continue assisting patients as we have for many years.

Charitable assistance provides a critical health safety net for our nation’s citizens living with chronic diseases that are complicated and expensive to treat. Patients who cannot afford their health insurance or their medications should be able to turn to charities for help. They should not have to lose their homes, or declare bankruptcy, or spend down their life’s savings to get the treatment they need. Insurers should not be permitted to shirk their responsibility to cover these patients, but when insurers tell people that a charity can’t help them pay their premium, that’s exactly what they are doing. The federal government must not allow this situation to stand.

AKF continues to condemn anecdotal reports of healthcare providers “steering” patients into private coverage by use of charitable assistance programs. AKF continues to take strong actions to guard against such behavior its own assistance program.

We must not lose sight of the fact that the primary issue at hand is that, because of insurers’ discriminatory actions, low-income Americans with chronic illnesses are at risk of losing their health coverage. Secretary Price can take action to protect Americans’ right to receive charitable assistance, while at the same time issuing sensible guidance to prevent health care providers or insurers from engaging in practices that interfere with patients choosing the plan that best meets their health care needs. The fact remains that of the 13 million people enrolled in Affordable Care Act plans, fewer than 4,000 nationwide are being assisted by the American Kidney Fund.

AKF has provided charitable premium assistance to low-income dialysis patients for two decades under a federally approved program. Without help from AKF, our grant recipients would not have access to the care they need and they would be financially devastated by kidney failure. Nearly two-thirds of AKF’s grant recipients use AKF’s help to pay their Medicare Part B and Medigap premiums. The remainder depend on AKF to stay insured under COBRA, employer plans and commercial plans, including a small number on the exchange.

It is important to note that the letter from Congress asks Secretary Price to clarify that charitable premium assistance from bona fide nonprofits should be available for all types of insurance plans. Insurers’ recent actions to deny premium payments for Medicare supplemental insurance (Medigap) places Medicare patients in great jeopardy. People on Medicare who lose their Medigap coverage as a result of this issue will be exposed to an unlimited 20 percent out-of-pocket cost, a financially devastating proposition for dialysis patients who are treated three times per week and frequently see numerous physicians and specialists. Without Medigap coverage, dialysis patients on Medicare are also much less likely to be able to have a kidney transplant.

We are grateful to the Members of Congress who have taken action to protect their constituents, and we are hopeful that Secretary Price will provide sensible guidance to address this issue on behalf of low-income, chronically ill Americans. Needing charitable assistance should never disqualify any American from having access to appropriate health coverage.

About the American Kidney Fund
As the nation’s leading nonprofit working on behalf of the 31 million Americans with kidney disease, the American Kidney Fund is dedicated to ensuring that every kidney patient has access to health care, and that every person at risk for kidney disease is empowered to prevent it. AKF provides a complete spectrum of programs and services: prevention outreach, top-rated health educational resources, and direct financial assistance enabling 1 in 5 U.S. dialysis patients to access lifesaving medical care, including dialysis and transplantation.

For more information, please visit www.KidneyFund.org, or connect with us on Facebook, Twitter and Instagram.

Alice Andors
American Kidney Fund
2402927053
email us here


Source: EIN Presswire

New York Magazine Recognizes Five Reproductive Medicine Associates of NY Physicians in their 2017 “Best Doctors” Issue

RMA of New York physicians recognized for excellence in reproductive endocrinology, obstetrics and gynecology and urology in treatment of infertility

NEW YORK, NY, UNITED STATES, May 31, 2017 /EINPresswire.com/ — Reproductive Medicine Associates of New York (RMA of New York), a Manhattan-based fertility practice globally renowned as a leader in reproductive care and for achieving exceptional birth rates through assisted reproductive technologies, has once again had several of its physicians recognized as the "Best Doctors" in the region by New York Magazine. This is the 16th year in a row that RMA of New York physicians have been named on the list, with this year's honorees being Alan B. Copperman, MD, Tanmoy Mukherjee, MD, Daniel E. Stein, MD, Jeffrey Klein, MD and Natan Bar-Chama, MD.

New York Magazine's "Best Doctors" list is based upon data provided by Castle Connolly Medical Ltd., a New York City research and information company that conducts an annual peer-review survey to determine the top ten percent of the region's physicians. Their annual database comprises roughly 6,000 physicians, and from that list a smaller list of 1,300 physicians is provided to New York Magazine for its annual publication.

RMA of New York is the Reproductive Endocrinology and Infertility subdivision of Mount Sinai Hospital, and has an international reputation as one of the top IVF centers in the world. Acknowledging the group's honorable achievement, Dr. Alan B. Copperman, Co-Director of the facility states, "At RMA of New York, our physicians are dedicated to providing compassionate and precise care to our patients. We are privileged to participate in scientific advances that directly impact care and help patients achieve their reproductive goals. We are proud that our professional team has been recognized by so many of our peers."

In addition to serving as co-director of RMA of New York, Dr. Alan B. Copperman is Director of the Division of Reproductive Endocrinology and Infertility, as well as the Vice-Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Hospital. Additionally, he is a Clinical Professor of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai. He is a frequent presenter at national and international meetings focusing on patient care and technology in assisted reproductive technologies, including in vitro fertilization, egg freezing, and ovum donation, and has published many award-winning papers and textbook chapters on fertility preservation and infertility treatment.

Dr Tanmoy Mukherjee is a board certified gynecologist and reproductive endocrinologist, is Associate Director of the Mount Sinai Division of Reproductive Endocrinology and co-director of Reproductive Medicine Associates of New York. He completed his residency at the Albert Einstein College of Medicine where he received the Leo M. Davidoff Society Award as well as the Schulman Award, and completed his fellowship at Mount Sinai Hospital.

Dr. Daniel Stein is the director of RMA of New York's Westside office and is Chief of Reproductive Endocrinology at Mount Sinai Roosevelt Hospital. Dr. Stein served for eight years as medical director of the In Vitro Fertilization program of the former Continuum Reproductive Center. He has lectured extensively on a variety of reproductive topics.

Dr. Jeffrey Klein leads RMA of New York's Westchester office and performs surgery at White Plains Hospital, Hudson Valley Hospital and St. John's Riverside Hospital. Dr. Klein is recognized for his compassionate care and his scientific expertise. He has published both research and clinical reports in peer-reviewed journals as well as chapters in textbooks on a wide range of reproductive topics including IVF, reproductive aging and egg donation.

Dr. Natan Bar-Chama, board certified urologist and male infertility specialist, is the director of the Center of Male Reproductive Health at RMA of New York, as well as director of Male Reproductive Medicine and Surgery and is on faculty in the departments of Urology and Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai. He is widely recognized for his skill and dedication to male reproductive medicine and microsurgical reconstruction for the treatment of male-factor infertility.

About Reproductive Medicine Associates of New York

Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a global leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training.

Allysa Mizerek
Reproductive Medicine Associates of New York
2127565777
email us here


Source: EIN Presswire

NeurAegis and Nanosyn announce partnership agreement

NeurAegis announced it has chosen Nanosyn to lead its chemistry efforts towards advancing novel and selective calpain-2 inhibitors to clinical candidates. 

POMONA, CALIFORNIA, UNITED STATES, May 31, 2017 /EINPresswire.com/ — NeurAegis and Nanosyn announce partnership agreement

May 30th, 2017. Pomona, CA and Santa Clara, CA
NeurAegis today announced that it has chosen Nanosyn, Inc., a leading US-based contract research provider of drug discovery and development services, to lead its chemistry efforts towards advancing novel and selective calpain-2 inhibitors to clinical candidates. 
NeurAegis has identified calpain-2 as a critical target in the pathway leading to neuronal death in a variety of neurological disorders resulting from insults or trauma, including traumatic brain injury and concussion, stroke, glaucoma, and other diseases associated with neuronal damage.
Dr. Baudry, NeurAegis CEO said “Nanosyn has an excellent track record in projects delivery. This partnership, combining NeurAegis' team of biologists, chemists and biotech leaders with a company with a proven record of advancing molecules to the clinic, provides for a unique synergy, which will speed up our efforts to develop the best selective calpain-2 inhibitor for neuroprotection.”
“We are excited about this project and look forward to working with NeurAegis' reputable team. Together we are well positioned to develop a new generation of much needed therapies for the patients with neurological disorders”, said Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc.

NeurAegis also added Drs. Norton Peet and Shujaath Mehdi to its Scientific Advisory Board.
Dr. Norton Peet
Dr. Norton Peet is an International R&D Consultant, and provides guidance and direction to industrial and academic organizations on drug discovery and development strategies. Dr. Peet currently serves as the Chief Scientific Officer for Chicago BioSolutions, a newly formed drug discovery company. In prior positions, Dr. Peet was Head of Medicinal Chemistry at Microbiotix, where he designed the chemistry for all internal and external research proposals. Dr. Peet is an organic chemist by training (UNL, MIT) and has spent much of his career in big pharma, with the string of companies that led to Aventis (now Sanofi). When he left Aventis in 2000 he was Head of Medicinal Chemistry and Distinguished Scientist. He joined the executive team at ArQule as Vice President of Discovery Alliances, where he managed alliances with several companies and also built a multidisciplinary Drug Discovery Group. In 2002, he became the CEO of Aurigene Discovery Technologies, a drug discovery company, and built laboratories in Boston (Lexington) and Bangalore (India). Dr. Peet has authored 175 journal articles and 70 US patents, and has contributed to 25 awarded grant applications. He has organized numerous international symposia and serves on several editorial and scientific advisory boards.
Dr. Shujaath Mehdi
Dr. Shujaath Mehdi is an expert in enzyme mechanisms and kinetics, in molecular aspects of drug design, discovery and development, and in translational medicine. Dr. Mehdi joined Merrell Dow (a predecessor company of Sanofi) in 1985 in Discovery Research after post-doctoral training in enzymology at Harvard University. Over the years he held the positions of Project Team Leader, Lab Head, and Group Leader of the Enzyme Chemistry group. Dr. Mehdi was instrumental in the design and characterization of enzyme inhibitors as drugs in multiple therapeutic areas. Prior to retirement, Dr. Mehdi led a cross-functional Translational Medicine group, whose responsibility was to apply translational principles to ensure the success of preclinical and clinical projects in the Immunoinflammation therapeutic area. After retirement from Sanofi in 2012 as a Distinguished Scientist, Dr. Mehdi has taught courses on ‘Drug Discovery Through Preclinical Development’ and on ‘Ethics of Science and Technology Management’ in the Master of Business and Science program at Rutgers University, and has lectured on Personalized Medicine at Rutgers and at Columbia University. He is the author of 50 publications, and is the co-inventor of 17 US Patents.

About NeurAegis
NeurAegis (www.neuraegis.com) has been founded to translate fundamental discoveries on the mechanisms of synaptic plasticity and neuronal survival/cell death into clinical applications. NeurAegis has identified neuroprotection as a key focus for research and development, because of the high unmet needs and tremendous research potential in this therapeutic area. Nevertheless, there is still no drug on the market that provides any significant degree of neuroprotection, especially within the crucial minutes to maximum of several hours following any brain insult that results in neuronal loss. NeurAegis company is privately held and self-funding. The company has laboratories in Pomona, CA.
Contact information: Michel Baudry, CEO, NeurAegis: m.baudry@neuraegis.com; tel: 949-468-7310.

About Nanosyn
Nanosyn (www.nanosyn.com) is a Contract Research and Manufacturing Organization providing integrated drug discovery and development services, medicinal chemistry, process chemistry, cGMP manufacturing, assay development, screening and profiling services, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA.
Contact information: Olga Issakova, Executive VP, Nanosyn: oissakova@nanosyn.com; tel: 650-269-3528

Michel Baudry
NeurAegis
9094698271
email us here


Source: EIN Presswire

Global Aquatic Feed Ingredients Market Research Report 2017 Analysis and Forecast to 2022

Aquatic Feed Ingredients Market

WiseGuyReports.com adds “Aquatic Feed Ingredients Market 2017 Global Analysis, Growth,Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Aquatic Feed Ingredients Market:

Executive Summary

This report studies Aquatic Feed Ingredients in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Addcon
Alltech
BioMar Group
Cargill
Cermaq
Archer Daniels Midland
BASF
Blue Ridge Aquaculture
Adisseo
Aliphos
Texas Natural Feeds
Hunan Tangrenshen
Canadian Organic Feeds
Land O'Lakes
American Abalone Farms
QualiTech
P. Pokphand
Selonda
Asmak
East Hope Group
Dalian Zhangzidao Fishery
New Hope Group

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1321158-global-aquatic-feed-ingredients-market-professional-survey-report-2017

By types, the market can be split into

Maize/Corn
Rice
Soybean
Fishmeal
Fish Oil
Other

By Application, the market can be split into

Fishes
Shellfishes
Shrimps
Other

By Regions, this report covers (we can add the regions/countries as you want)

North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/1321158-global-aquatic-feed-ingredients-market-professional-survey-report-2017

Table of Contents

Global Aquatic Feed Ingredients Market Professional Survey Report 2017
1 Industry Overview of Aquatic Feed Ingredients
1.1 Definition and Specifications of Aquatic Feed Ingredients
1.1.1 Definition of Aquatic Feed Ingredients
1.1.2 Specifications of Aquatic Feed Ingredients
1.2 Classification of Aquatic Feed Ingredients
1.2.1 Maize/Corn
1.2.2 Rice
1.2.3 Soybean
1.2.4 Fishmeal
1.2.5 Fish Oil
1.2.6 Other
1.3 Applications of Aquatic Feed Ingredients
1.3.1 Fishes
1.3.2 Shellfishes
1.3.3 Shrimps
1.3.4 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Aquatic Feed Ingredients
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Aquatic Feed Ingredients
2.3 Manufacturing Process Analysis of Aquatic Feed Ingredients
2.4 Industry Chain Structure of Aquatic Feed Ingredients

3 Technical Data and Manufacturing Plants Analysis of Aquatic Feed Ingredients
3.1 Capacity and Commercial Production Date of Global Aquatic Feed Ingredients Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Aquatic Feed Ingredients Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Aquatic Feed Ingredients Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Aquatic Feed Ingredients Major Manufacturers in 2016

4 Global Aquatic Feed Ingredients Overall Market Overview
4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2012-2017E Global Aquatic Feed Ingredients Capacity and Growth Rate Analysis
4.2.2 2016 Aquatic Feed Ingredients Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2012-2017E Global Aquatic Feed Ingredients Sales and Growth Rate Analysis
4.3.2 2016 Aquatic Feed Ingredients Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 2012-2017E Global Aquatic Feed Ingredients Sales Price
4.4.2 2016 Aquatic Feed Ingredients Sales Price Analysis (Company Segment)

5 Aquatic Feed Ingredients Regional Market Analysis
5.1 North America Aquatic Feed Ingredients Market Analysis
5.1.1 North America Aquatic Feed Ingredients Market Overview
5.1.2 North America 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.1.4 North America 2016 Aquatic Feed Ingredients Market Share Analysis
5.2 China Aquatic Feed Ingredients Market Analysis
5.2.1 China Aquatic Feed Ingredients Market Overview
5.2.2 China 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.2.4 China 2016 Aquatic Feed Ingredients Market Share Analysis
5.3 Europe Aquatic Feed Ingredients Market Analysis
5.3.1 Europe Aquatic Feed Ingredients Market Overview
5.3.2 Europe 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.3.4 Europe 2016 Aquatic Feed Ingredients Market Share Analysis
5.4 Southeast Asia Aquatic Feed Ingredients Market Analysis
5.4.1 Southeast Asia Aquatic Feed Ingredients Market Overview
5.4.2 Southeast Asia 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Southeast Asia 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.4.4 Southeast Asia 2016 Aquatic Feed Ingredients Market Share Analysis
5.5 Japan Aquatic Feed Ingredients Market Analysis
5.5.1 Japan Aquatic Feed Ingredients Market Overview
5.5.2 Japan 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Japan 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.5.4 Japan 2016 Aquatic Feed Ingredients Market Share Analysis
5.6 India Aquatic Feed Ingredients Market Analysis
5.6.1 India Aquatic Feed Ingredients Market Overview
5.6.2 India 2012-2017E Aquatic Feed Ingredients Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India 2012-2017E Aquatic Feed Ingredients Sales Price Analysis
5.6.4 India 2016 Aquatic Feed Ingredients Market Share Analysis

6 Global 2012-2017E Aquatic Feed Ingredients Segment Market Analysis (by Type)
6.1 Global 2012-2017E Aquatic Feed Ingredients Sales by Type
6.2 Different Types of Aquatic Feed Ingredients Product Interview Price Analysis
6.3 Different Types of Aquatic Feed Ingredients Product Driving Factors Analysis
6.3.1 Maize/Corn of Aquatic Feed Ingredients Growth Driving Factor Analysis
6.3.2 Rice of Aquatic Feed Ingredients Growth Driving Factor Analysis
6.3.3 Soybean of Aquatic Feed Ingredients Growth Driving Factor Analysis
6.3.4 Fishmeal of Aquatic Feed Ingredients Growth Driving Factor Analysis
6.3.5 Fish Oil of Aquatic Feed Ingredients Growth Driving Factor Analysis
6.3.6 Other of Aquatic Feed Ingredients Growth Driving Factor Analysis

7 Global 2012-2017E Aquatic Feed Ingredients Segment Market Analysis (by Application)
7.1 Global 2012-2017E Aquatic Feed Ingredients Consumption by Application
7.2 Different Application of Aquatic Feed Ingredients Product Interview Price Analysis
7.3 Different Application of Aquatic Feed Ingredients Product Driving Factors Analysis
7.3.1 Fishes of Aquatic Feed Ingredients Growth Driving Factor Analysis
7.3.2 Shellfishes of Aquatic Feed Ingredients Growth Driving Factor Analysis
7.3.3 Shrimps of Aquatic Feed Ingredients Growth Driving Factor Analysis
7.3.4 Other of Aquatic Feed Ingredients Growth Driving Factor Analysis

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1321158

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Liposomes Drug Delivery Market 2017 Industry Key Players, Trends, Sales, Supply,Demand,Analysis,Forecast to 2022

Liposomes Drug Delivery Market

WiseGuyReports.com adds “Liposomes Drug Delivery Market 2017 Global Analysis, Growth, Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Liposomes Drug Delivery Market:

Executive Summary

This report studies the global Liposomes Drug Delivery market, analyzes and researches the Liposomes Drug Delivery development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Johnson & Johnson
Gilead Sciences
Luye Pharma
Sun Pharmaceutical
Pacira
Fudan-Zhangjiang
Sigma-Tau Group
Teva Pharmaceutical
CSPC
Novartis
Crucell
Celsion Corporation
Kingond Pharm
Shanghai New Asia
Spectrum Pharmaceuticals
Market segment by Regions/Countries, this report covers

United States
EU
Japan
China
India
Southeast Asia
Market segment by Application, Liposomes Drug Delivery can be split into

Fungal Infection Therapy
Cancer Therapy
If you have any special requirements, please let us know and we will offer you the report as you want.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1321728-global-liposomes-drug-delivery-market-size-status-and-forecast-2022

Table of Contents

Global Liposomes Drug Delivery Market Size, Status and Forecast 2022
1 Industry Overview of Liposomes Drug Delivery
1.1 Liposomes Drug Delivery Market Overview
1.1.1 Liposomes Drug Delivery Product Scope
1.1.2 Market Status and Outlook
1.2 Global Liposomes Drug Delivery Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Liposomes Drug Delivery Market by End Users/Application
1.3.1 Fungal Infection Therapy
1.3.2 Cancer Therapy

2 Global Liposomes Drug Delivery Competition Analysis by Players
2.1 Liposomes Drug Delivery Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

4 Global Liposomes Drug Delivery Market Size by Application (2012-2017)
4.1 Global Liposomes Drug Delivery Market Size by Application (2012-2017)
4.2 Potential Application of Liposomes Drug Delivery in Future
4.3 Top Consumer/End Users of Liposomes Drug Delivery

5 United States Liposomes Drug Delivery Development Status and Outlook
5.1 United States Liposomes Drug Delivery Market Size (2012-2017)
5.2 United States Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

6 EU Liposomes Drug Delivery Development Status and Outlook
6.1 EU Liposomes Drug Delivery Market Size (2012-2017)
6.2 EU Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

7 Japan Liposomes Drug Delivery Development Status and Outlook
7.1 Japan Liposomes Drug Delivery Market Size (2012-2017)
7.2 Japan Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

8 China Liposomes Drug Delivery Development Status and Outlook
8.1 China Liposomes Drug Delivery Market Size (2012-2017)
8.2 China Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

9 India Liposomes Drug Delivery Development Status and Outlook
9.1 India Liposomes Drug Delivery Market Size (2012-2017)
9.2 India Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Liposomes Drug Delivery Development Status and Outlook
10.1 Southeast Asia Liposomes Drug Delivery Market Size (2012-2017)
10.2 Southeast Asia Liposomes Drug Delivery Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions and Application (2017-2022)
11.1 Global Liposomes Drug Delivery Market Size (Value) by Regions (2017-2022)
11.1.1 United States Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.1.2 EU Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.1.3 Japan Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.1.4 China Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.1.5 India Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.1.6 Southeast Asia Liposomes Drug Delivery Revenue and Growth Rate (2017-2022)
11.2 Global Liposomes Drug Delivery Market Size (Value) by Application (2017-2022)
11.3 The Market Drivers in Future

12 Liposomes Drug Delivery Market Dynamics
12.1 Liposomes Drug Delivery Market Opportunities
12.2 Liposomes Drug Delivery Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Liposomes Drug Delivery Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Liposomes Drug Delivery Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application

13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1321728

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

American Association of Suicidology Announces New Executive Director

Together we can work to bring suicide prevention to the forefront of our national public health dialogue and expand its rightful place as a national priority.”

— Colleen Creighton

WASHINGTON, D.C., US, May 31, 2017 /EINPresswire.com/ — After an exhaustive nationwide search, The American Association of Suicidology (AAS) is pleased to announce the appointment of Colleen Creighton, MA, as its Executive Director.

Colleen brings 15 years of experience in growing and leading national nonprofit foundations and expertise in creating innovative partnerships. Her previous work in advocacy at various levels of government, engaging both federal representatives and agencies, promises to bring substantial value to AAS’s national efforts in suicide prevention.

“The board and I are excited to have Colleen as the head of the AAS team. Her leadership and nonprofit management expertise are vital to the organization as we build on the foundations built by our members,” said AAS President, Julie Cerel, Ph.D.

“Colleen offers AAS an entrepreneurial spirit, which will guide the organization and the field of suicide prevention to reach new audiences and populations in ever more effective ways,” said AAS Chairman Anthony Wood. “She brings experience from the larger prevention field, strengthening the agency’s commitment to outcomes-based public health approaches in suicide prevention,” says Wood.

“I’m honored to be joining the American Association of Suicidology at such a pivotal time,” Creighton said in a statement. “AAS has an incredibly powerful reputation, a wonderful and dedicated staff, and a diverse and engaging membership. I am dedicated to combining a personal passion for this cause with more than 15 years in leading nonprofit foundations to help AAS grow as an organization. Together we can work to bring suicide prevention to the forefront of our national public health dialogue and expand its rightful place as a national priority.”

The AAS Board extends its gratitude to Amy J. Kulp who has served as Interim Executive Director since 2015 and who will continue in her previous role as Deputy Director.

###

About AAS: Founded in 1968 by pioneering Psychologist Dr. Edwin S. Shneidman (1918-2009), AAS is based in Washington DC, it promotes suicide prevention as a research discipline, public awareness programs, public education and training for professionals and volunteers. The membership of AAS includes mental health and public health professionals, researchers, suicide prevention and crisis intervention centers, school districts, crisis center volunteers, survivors of suicide loss, attempt survivors, and a variety of lay persons who have in interest in suicide prevention. You can learn more about AAS at www.suicidology.org.

For the Media: Responsible reporting on suicide, including stories of hope and resilience, can prevent more suicides. Please visit www.reportingonsuicide.org for more information

Amy Kulp, M.S.
American Association of Suicidology
202-237-2280
email us here


Source: EIN Presswire

3D Printing in Healthcare Market 2017 Global Industry Analysis, Opportunities, Size, Trends, Growth and Forecast 2022

Wiseguyreports.Com Publish New Report On-“3D Printing in Healthcare Market 2017 Global Industry Analysis, Opportunities, Size, Trends, Growth and Forecast 2022”

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ —

3D Printing in Healthcare Market 2017

Global 3D Printing in Healthcare market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Bio-Rad Laboratories
EnvisionTEC
Materialise NV
Stratasys Inc.
Organovo
SOLS
Simbionix
Metamason
RegenHU Ltd.
Youbionic
Bio3D Technologies Pte Ltd
3D Matters Pte Ltd.
3D Systems Corporation (3DS)
Ekso Bionics
Roche Pharmaceuticals
Renishaw plc.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1326975-global-3d-printing-in-healthcare-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of 3D Printing in Healthcare in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Extrusion
Photo-polymerization
Laser Beam Melting
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of 3D Printing in Healthcare for each application, including
Medical Devices
Bio-printing
Others

Complete Report Details @ https://www.wiseguyreports.com/reports/1326975-global-3d-printing-in-healthcare-market-research-report-2017

Table of Contents

Global 3D Printing in Healthcare Market Research Report 2017
1 3D Printing in Healthcare Market Overview
1.1 Product Overview and Scope of 3D Printing in Healthcare
1.2 3D Printing in Healthcare Segment by Type (Product Category)
1.2.1 Global 3D Printing in Healthcare Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global 3D Printing in Healthcare Production Market Share by Type (Product Category) in 2016
1.2.3 Extrusion
1.2.4 Photo-polymerization
1.2.5 Laser Beam Melting
1.2.6 Others
1.3 Global 3D Printing in Healthcare Segment by Application
1.3.1 3D Printing in Healthcare Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Medical Devices
1.3.3 Bio-printing
1.3.4 Others
1.4 Global 3D Printing in Healthcare Market by Region (2012-2022)
1.4.1 Global 3D Printing in Healthcare Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of 3D Printing in Healthcare (2012-2022)
1.5.1 Global 3D Printing in Healthcare Revenue Status and Outlook (2012-2022)
1.5.2 Global 3D Printing in Healthcare Capacity, Production Status and Outlook (2012-2022)
………….

7 Global 3D Printing in Healthcare Manufacturers Profiles/Analysis
7.1 Bio-Rad Laboratories
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 3D Printing in Healthcare Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Bio-Rad Laboratories 3D Printing in Healthcare Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 EnvisionTEC
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 3D Printing in Healthcare Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 EnvisionTEC 3D Printing in Healthcare Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Materialise NV
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 3D Printing in Healthcare Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Materialise NV 3D Printing in Healthcare Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 Stratasys Inc.
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 3D Printing in Healthcare Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
..…..Continued

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1326975

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
email us here


Source: EIN Presswire

Global Omega-3 Supplements Market 2017 Key Players, Supply, Consumption, Demand, Growth, Analysis and Forecast to 2022

Omega-3 Supplements Market

WiseGuyReports.com adds “Omega-3 Supplements Market 2017 Global Analysis, Growth, Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Omega-3 Supplements Market:

Executive Summary

In this report, the global Omega-3 Supplements market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Omega-3 Supplements in these regions, from 2012 to 2022 (forecast), covering

North America
Europe
China
Japan
Southeast Asia
India

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1321716-global-omega-3-supplements-market-research-report-2017

Global Omega-3 Supplements market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Nutrigold Inc
Reckitt Benckiser Group plc
Nordic Naturals Inc
Pharma Nord B.V
Now Foods
I Health Inc
Aker BioMarine AS
Pharmavite LLC
Cederroth AB
Glaxosmithkline PLC
Carlson Laboratories
Dr C's Omega 3's
Jarrow Formulas
Terra-Medica
Tranquility Labs LLC
Coromega

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Fish Oil
Krill Oil
Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Omega-3 Supplements for each application, including

Food & Beverages
Pharmaceutical
Pet & Animal Feed

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/1321716-global-omega-3-supplements-market-research-report-2017

Table of Contents

Global Omega-3 Supplements Market Research Report 2017
1 Omega-3 Supplements Market Overview
1.1 Product Overview and Scope of Omega-3 Supplements
1.2 Omega-3 Supplements Segment by Type (Product Category)
1.2.1 Global Omega-3 Supplements Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Omega-3 Supplements Production Market Share by Type (Product Category) in 2016
1.2.3 Fish Oil
1.2.4 Krill Oil
1.2.5 Others
1.3 Global Omega-3 Supplements Segment by Application
1.3.1 Omega-3 Supplements Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Food & Beverages
1.3.3 Pharmaceutical
1.3.4 Pet & Animal Feed
1.4 Global Omega-3 Supplements Market by Region (2012-2022)
1.4.1 Global Omega-3 Supplements Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Omega-3 Supplements (2012-2022)
1.5.1 Global Omega-3 Supplements Revenue Status and Outlook (2012-2022)
1.5.2 Global Omega-3 Supplements Capacity, Production Status and Outlook (2012-2022)

2 Global Omega-3 Supplements Market Competition by Manufacturers
2.1 Global Omega-3 Supplements Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Omega-3 Supplements Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Omega-3 Supplements Production and Share by Manufacturers (2012-2017)
2.2 Global Omega-3 Supplements Revenue and Share by Manufacturers (2012-2017)
2.3 Global Omega-3 Supplements Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Omega-3 Supplements Manufacturing Base Distribution, Sales Area and Product Type
2.5 Omega-3 Supplements Market Competitive Situation and Trends
2.5.1 Omega-3 Supplements Market Concentration Rate
2.5.2 Omega-3 Supplements Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

7 Global Omega-3 Supplements Manufacturers Profiles/Analysis
7.1 Nutrigold Inc
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Omega-3 Supplements Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Nutrigold Inc Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Reckitt Benckiser Group plc
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Omega-3 Supplements Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Reckitt Benckiser Group plc Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Nordic Naturals Inc
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Omega-3 Supplements Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Nordic Naturals Inc Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 Pharma Nord B.V
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Omega-3 Supplements Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Pharma Nord B.V Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 Now Foods
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Omega-3 Supplements Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Now Foods Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 I Health Inc
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Omega-3 Supplements Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 I Health Inc Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Aker BioMarine AS
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Omega-3 Supplements Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Aker BioMarine AS Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Pharmavite LLC
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Omega-3 Supplements Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Pharmavite LLC Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Cederroth AB
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Omega-3 Supplements Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Cederroth AB Omega-3 Supplements Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 Glaxosmithkline PLC
7.11 Carlson Laboratories
7.12 Dr C's Omega 3's
7.13 Jarrow Formulas
7.14 Terra-Medica
7.15 Tranquility Labs LLC
7.16 Coromega

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1321716

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Chlorella Market 2017 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast to 2022

Chlorella Market

WiseGuyReports.com adds “Chlorella Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Chlorella Market:

Executive Summary

This report studies Chlorella in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

FEMICO
Taiwan Chlorella
Vedan
Febico
Wilson
Gong Bih
Yaeyama
Sun Chlorella
King Dnarmsa
Lvanqi
Wuli Lvqi
Tianjian

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1321145-global-chlorella-market-professional-survey-report-2017

By types, the market can be split into

Capsules
Granules
Other

By Application, the market can be split into

Food
Health Care
Medicinal
Other

By Regions, this report covers (we can add the regions/countries as you want)

North America
China
Europe
Southeast Asia
Japan
India

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/1321145-global-chlorella-market-professional-survey-report-2017

Table of Contents

Global Chlorella Market Professional Survey Report 2017
1 Industry Overview of Chlorella
1.1 Definition and Specifications of Chlorella
1.1.1 Definition of Chlorella
1.1.2 Specifications of Chlorella
1.2 Classification of Chlorella
1.2.1 Capsules
1.2.2 Granules
1.2.3 Other
1.3 Applications of Chlorella
1.3.1 Food
1.3.2 Health Care
1.3.3 Medicinal
1.3.4 Other
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Chlorella
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Chlorella
2.3 Manufacturing Process Analysis of Chlorella
2.4 Industry Chain Structure of Chlorella

3 Technical Data and Manufacturing Plants Analysis of Chlorella
3.1 Capacity and Commercial Production Date of Global Chlorella Major Manufacturers in 2016
3.2 Manufacturing Plants Distribution of Global Chlorella Major Manufacturers in 2016
3.3 R&D Status and Technology Source of Global Chlorella Major Manufacturers in 2016
3.4 Raw Materials Sources Analysis of Global Chlorella Major Manufacturers in 2016

4 Global Chlorella Overall Market Overview
4.1 2012-2017E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 2012-2017E Global Chlorella Capacity and Growth Rate Analysis
4.2.2 2016 Chlorella Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 2012-2017E Global Chlorella Sales and Growth Rate Analysis
4.3.2 2016 Chlorella Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 2012-2017E Global Chlorella Sales Price
4.4.2 2016 Chlorella Sales Price Analysis (Company Segment)

5 Chlorella Regional Market Analysis
5.1 North America Chlorella Market Analysis
5.1.1 North America Chlorella Market Overview
5.1.2 North America 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America 2012-2017E Chlorella Sales Price Analysis
5.1.4 North America 2016 Chlorella Market Share Analysis
5.2 China Chlorella Market Analysis
5.2.1 China Chlorella Market Overview
5.2.2 China 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.2.3 China 2012-2017E Chlorella Sales Price Analysis
5.2.4 China 2016 Chlorella Market Share Analysis
5.3 Europe Chlorella Market Analysis
5.3.1 Europe Chlorella Market Overview
5.3.2 Europe 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.3.3 Europe 2012-2017E Chlorella Sales Price Analysis
5.3.4 Europe 2016 Chlorella Market Share Analysis
5.4 Southeast Asia Chlorella Market Analysis
5.4.1 Southeast Asia Chlorella Market Overview
5.4.2 Southeast Asia 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Southeast Asia 2012-2017E Chlorella Sales Price Analysis
5.4.4 Southeast Asia 2016 Chlorella Market Share Analysis
5.5 Japan Chlorella Market Analysis
5.5.1 Japan Chlorella Market Overview
5.5.2 Japan 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Japan 2012-2017E Chlorella Sales Price Analysis
5.5.4 Japan 2016 Chlorella Market Share Analysis
5.6 India Chlorella Market Analysis
5.6.1 India Chlorella Market Overview
5.6.2 India 2012-2017E Chlorella Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India 2012-2017E Chlorella Sales Price Analysis
5.6.4 India 2016 Chlorella Market Share Analysis

6 Global 2012-2017E Chlorella Segment Market Analysis (by Type)
6.1 Global 2012-2017E Chlorella Sales by Type
6.2 Different Types of Chlorella Product Interview Price Analysis
6.3 Different Types of Chlorella Product Driving Factors Analysis
6.3.1 Capsules of Chlorella Growth Driving Factor Analysis
6.3.2 Granules of Chlorella Growth Driving Factor Analysis
6.3.3 Other of Chlorella Growth Driving Factor Analysis

7 Global 2012-2017E Chlorella Segment Market Analysis (by Application)
7.1 Global 2012-2017E Chlorella Consumption by Application
7.2 Different Application of Chlorella Product Interview Price Analysis
7.3 Different Application of Chlorella Product Driving Factors Analysis
7.3.1 Food of Chlorella Growth Driving Factor Analysis
7.3.2 Health Care of Chlorella Growth Driving Factor Analysis
7.3.3 Medicinal of Chlorella Growth Driving Factor Analysis
7.3.4 Other of Chlorella Growth Driving Factor Analysis

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1321145

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Pharmaceutical Fine Chemicals Market 2017 Share, Trend, Segmentation and Forecast to 2022

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer

PUNE, INDIA, May 31, 2017 /EINPresswire.com/ — Summary

Global Pharmaceutical Fine Chemicals market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Abbott
Akzo Nobel
Albemarle Corporation
AstraZeneca
BASF
Boehringer Ingelheim
Clariant
Eastman Chemical
Evonik Industries
GlaxoSmithKlein
Lonza Group
Merck and co.
Roche
Royal DSM
The Dow Chemical Company

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pharmaceutical Fine Chemicals in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Big Molecules
Small Molecules

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Pharmaceutical Fine Chemicals for each application, including
Non Proprietary Drugs
Poprietary Drugs

At any Query @ https://www.wiseguyreports.com/enquiry/1327201-global-pharmaceutical-fine-chemicals-market-research-report-2017

Table of Contents

Global Pharmaceutical Fine Chemicals Market Research Report 2017
1 Pharmaceutical Fine Chemicals Market Overview
1.1 Product Overview and Scope of Pharmaceutical Fine Chemicals
1.2 Pharmaceutical Fine Chemicals Segment by Type (Product Category)
1.2.1 Global Pharmaceutical Fine Chemicals Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Pharmaceutical Fine Chemicals Production Market Share by Type (Product Category) in 2016
1.2.3 Big Molecules
1.2.4 Small Molecules
1.3 Global Pharmaceutical Fine Chemicals Segment by Application
1.3.1 Pharmaceutical Fine Chemicals Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Non Proprietary Drugs
1.3.3 Poprietary Drugs
1.4 Global Pharmaceutical Fine Chemicals Market by Region (2012-2022)
1.4.1 Global Pharmaceutical Fine Chemicals Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Pharmaceutical Fine Chemicals (2012-2022)
1.5.1 Global Pharmaceutical Fine Chemicals Revenue Status and Outlook (2012-2022)
1.5.2 Global Pharmaceutical Fine Chemicals Capacity, Production Status and Outlook (2012-2022)

7 Global Pharmaceutical Fine Chemicals Manufacturers Profiles/Analysis
7.1 Abbott
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Abbott Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Akzo Nobel
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Akzo Nobel Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Albemarle Corporation
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Albemarle Corporation Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview
7.4 AstraZeneca
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 AstraZeneca Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.4.4 Main Business/Business Overview
7.5 BASF
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 BASF Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.5.4 Main Business/Business Overview
7.6 Boehringer Ingelheim
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Boehringer Ingelheim Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.6.4 Main Business/Business Overview
7.7 Clariant
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Clariant Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.7.4 Main Business/Business Overview
7.8 Eastman Chemical
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Eastman Chemical Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.8.4 Main Business/Business Overview
7.9 Evonik Industries
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Evonik Industries Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.9.4 Main Business/Business Overview
7.10 GlaxoSmithKlein
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Pharmaceutical Fine Chemicals Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 GlaxoSmithKlein Pharmaceutical Fine Chemicals Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.10.4 Main Business/Business Overview
7.11 Lonza Group
7.12 Merck and co.
7.13 Roche
7.14 Royal DSM
7.15 The Dow Chemical Company

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1327201

Continued….

NORAH TRENT
Wise Guy Reports
+91 841 198 5042
email us here


Source: EIN Presswire